

Tirzepatide Dosing Chart

A dual GIP and GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management, dosed once weekly. Commonly discussed doses: 2.5 mg–15 mg. Commonly discussed protocols begin at the lowest step and increase no faster than every four weeks. Weekly dosing.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

FDA-approved as a prescription drug (Mounjaro, Zepbound). Compounded tirzepatide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or quality.

5 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
1 mL	5	50 u	100 u	—	—	—	—
2 mL	2.5	100 u	—	—	—	—	—
3 mL	1.67	—	—	—	—	—	—

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
1 mL	10	25 u	50 u	75 u	100 u	—	—
2 mL	5	50 u	100 u	—	—	—	—
3 mL	3.33	75 u	—	—	—	—	—

15 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
1 mL	15	16.7 u	33.3 u	50 u	66.7 u	83.3 u	100 u
2 mL	7.5	33.3 u	66.7 u	100 u	—	—	—
3 mL	5	50 u	100 u	—	—	—	—

20 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
1 mL	20	12.5 u	25 u	37.5 u	50 u	62.5 u	75 u
2 mL	10	25 u	50 u	75 u	100 u	—	—
3 mL	6.67	37.5 u	75 u	—	—	—	—

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/tirzepatide

Tirzepatide dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.